MedPath

Recurrent Respiratory Papillomatosis and Extraesophageal Reflux

Not Applicable
Completed
Conditions
Recurrent Respiratory Papillomatosis
Extra Oesophageal Reflux
Laryngeal Cyst
Registration Number
NCT02592902
Lead Sponsor
University Hospital Ostrava
Brief Summary

The purpose of the study was to determine, whether patients with recurrent respiratory papillomatosis (RRP) suffer from extra oesophageal reflux more often than patients with laryngeal cyst (control group).

Detailed Description

Recurrent respiratory papillomatosis (RRP) is a chronic viral disease, which affects children and adults as well. It is characterised by grow of squamous cell tumours on mucosa of aerodigestive tract, with predilection for the larynx. The disease is caused by the human papillomavirus (HPV). However, in contrast to the low incidence of RRP, HPV prevalence is common. It is indicated that other factors may contribute to the pathogenesis of RRP. One such factor might be extraesophageal reflux (EER). We investigated whether patients with RRP suffer more often from EER.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
60
Inclusion Criteria
  • age 1-75 years
  • cooperating patients with laryngeal papillomatosis
  • patients tolerating impedance probe
  • signed informed consent, consent with the examinations
  • control group of patients with a cyst or vocal cord polyp (reflux finding score 0-2) and/or patients indicated to augmentation, medialization or lateralization of the vocal cords
Exclusion Criteria
  • patients non-tolerating impedance catheter
  • patients who do not understand Czech language
  • patients who do not proclaim consent with enrolment into the study
  • patients who do not proclaim consent with the planned examinations
  • patients after surgical treatment of tumour of the swallowing or respiratory tract

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Primary Outcome Measures
NameTimeMethod
Occurrence of EER (percentage)36 months

The occurrence of extra oesophageal reflux will be assessed in both study groups.

Secondary Outcome Measures
NameTimeMethod
Presence of pepsin36 months

The presence of pepsin (yes-no) will be assessed in both study groups.

Trial Locations

Locations (1)

University Hospital Ostrava

🇨🇿

Ostrava-Poruba, Czech Republic, Czechia

University Hospital Ostrava
🇨🇿Ostrava-Poruba, Czech Republic, Czechia

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.